Title of the cohort

Luxembourg Cohort

Acronym for cohort


Name of Principal Investigator
First name Sophie
Address of institution where award is held
Street Address1 A-B rue Thomas Edison




Contact email
Funding source

Ministry of Research
Ministry of Health

1. The cohort includes, or expects to include, incidence of the following conditions
  • Parkinson’s disease
  • Neurodegenerative disease in general
When studies on the above condition(s) are expected to become possible

2011 – 2015

2a. Stated aim of the cohort

To study particularly mechanism of development of parkinson disease, diabetes and lung cancer, for propose method of pre-diagnosis, and personalised medicine

2b. Features distinguishing this cohort from other population cohorts

this cohort will be built from EHES cross sectional survey, and with volonteers.

research in proteomics and metalobomics are priorities

3a. i) Number of publications that involve use of cohort to date
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)
3c. Information (i.e. research findings) expected to be gained from the population cohort
4a. Study criteria: age range of participants at recruitment
Age in years from:18 years
To (‘until death’ if applicable):75 years
4b. Study criteria: inclusion criteria

people with parkinson diseases
people with diabetes
people with cancer
people who participate in EHES cross sectional study

4c. Study criteria: exclusion criteria

institutionalised people

5. Size of the cohort (i.e. number of participants enrolled)

More than 15,000

6a. Measures used to characterise participants

age, gender, ethnical informations, socio economic conditions, educational conditions, diseases and medications, family diseases, lifestyle (tobacco, alcoohol, physical activity, nutrition), work situation, environmental conditions, health status, health care using, cognitiv assessement, anthropometric measures, blood pressure, biological analysis, genetic informations

6b. Additional measures for participants with a clinical disorder

if diabetes, more blood analysis and family disease if parkinson, more blood analysis, some neurological tests, family disease

6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)


7. Study design

Prospective cohort

8. Cases matched by
  • Age
  • Sex
  • Co-morbidities
  • Cognitive function
  • Physical ability
9a. Does the study include a specialised subset of control participants


9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date


10a. ii) Data collection end date


10a iii) Data collection for this study is

At the planning stage

10b. Plans to continue the cohort study beyond the current projected end date
  • Yes – intend to apply for funding
11. Data collected
  • Only through the study
  • Through links to medical records
12. System in place to enable re-contact with patients for future studies

Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

13a. Format and availability of data stored in a database
Yes/No% available
Data summarised in database Yes
Database is web-based Yes
Database on spreadsheet
Database is on paper
Other (specify)
Language used:

french, german, english, portugues

13b. Format and availability of data held as individual records
Language used:
14a. Are data available to other groups


14b. Access policy/mechanisms for access if data are available to other groups
  • Access through collaboration with PI only
  • Access independent of collaboration with PI
  • Access Committee mechanism
  • National access International access
  • Access to industry
  • Access for pilot studies permitted
  • Access restricted to peer-reviewed work
  • Applicant needs to provide separate external ethics approval
15. Data sharing policy specified as a condition of use

Data made publicly available after a specified time point

16a. Are tissues/samples/DNA available to other groups


16b. i) Description of available tissues/samples/DNA
  • Living donors:blood
  • Living donors: blood derivatives
  • Living donors: DNA
16b. ii) Form available tissues/samples/DNA are supplied in
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data


17. Is information on biological characteristics available to other groups
  • Yes, for all the cohort

    Types: Population Cohorts
    Member States: Luxembourg
    Diseases: Neurodegenerative disease in general, Parkinson's disease & PD-related disorders
    Years: N/A
    Database Categories: N/A
    Database Tags: N/A

    Export as PDF